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ABSTRACT 
The inclusion of racial/ethnic minorities in treatment outcomes trials for children and 
adolescents with depression and anxiety is essential, particularly given the assumption, 
required by the NIH, that racial diversity is important to the generalizability of clinical 
trial outcomes.  A search for randomized clinical trials on the treatment of child and 
adolescent depression and anxiety was conducted using the Medline and Psychinfo 
databases.  These were then reviewed to determine whether race or ethnicity were 1) 
factored into recruitment strategies; 2) represented in the trial sample; and 3) included in 
moderator analyses to determine the extent to which they may influence trial outcomes. 
37 original and 13 follow-up trials were identified (total N = 3330).  None identified 
strategies for targeted recruitment of racial/ethnic minorities.  Six did not report race.  All 
minority groups except for Native Americans are underrepresented as compared to 2000 
US Census figures; however, only one study reported Native Americans as participants.  
Overall, 67% of the sample was Caucasian, 26% minority, and 6% unreported.  There 
was no trend in minority representation by year.  Most studies reviewed do report the 
ethnic breakdown of their sample population, although methods vary.  Six studies, three 
original and three follow-up, explored the ethnicity as a moderator. Without an increased 
presence of minorities in clinical trials, it is unclear that the results of these studies can 
reliably generalize to a diverse population.  The importance of studies in minority 
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Depression is, according to the World Health Organization (WHO), “the leading cause of 
disability as measured by YLDs1 and the 4th leading contributor to the global burden of 
disease (DALYs2) in 2000.” [1]  Perhaps even more worrisome, studies seem to indicate 
that the presentation of depression during childhood or adolescence is common, often 
chronic, and associated with high levels of morbidity and mortality from suicide. [2] The 
National Comorbidity Study, while it did not focus exclusively on children and 
adolescents, found the highest 30-day prevalence in the youngest age group studied, 15-
24 year olds. [2] In a 10-year review of depression, Birmaher et al. report that the 
estimated lifetime prevalence of depression in adolescents ranges from 15% to 20%. [3]  
It is also noted that the suicide rate for teenagers has increased rapidly in the latter part of 
the 20th century, quadrupling since 1950.  This rapid rise also holds true for African-
Americans, especially in more recent years.  According to the Centers for Disease 
Control (CDC), African-American males aged 15-19 experienced a 146% increase in 
suicide rate between 1980 and 1995. [4] In a study of suicide in over 1,000 
predominantly poor African-American adolescents, Iolongo et al. found the lifetime 
prevalence of suicidal ideation to be 5.3%. [5] A 2004 study reported that lifetime 
prevalence of major depressive disorder was 9.4% in a demographically similar 
population. [6] 
 
                                                 
1 Years lived with disability. 
2 Disability-Adjusted Life Years 
 
 
Although the exact causes and/or mechanisms of depression are unclear, the possibility of 
a genetic component to the disease remains.  Birmaher et al. report that children who 
grow up with at least one depressed parent are much more likely to experience an episode 
of major depression in their lifetime. [3] 
 
Anxiety 
Anxiety disorders, the most common mental health disorders, similarly affect populations 
worldwide. “Anxiety disorders not only are common in the United States, but they are 
ubiquitous across human cultures.” [7] Among adults in the United States aged 18-54, the 
estimated 1-year prevalence is over 16%. [7] As with major depressive disorder, there is 
significant chronicity and morbidity associated with anxiety disorders.  Some studies 
have found anxiety disorders, specifically panic disorder, to be linked to suicide attempts.  
[8] Again, as with depression, anxiety disorders appear to be common in children and 
adolescents.  Various studies of anxiety disorders report that prevalence can range from 
5.7% to 17.7%.  In a 21-year longitudinal study of almost 1000 children from New 
Zealand, Woodward and Fergusson found the presence of an anxiety disorder in 
adolescence to be associated with a number of later negative outcomes.  These include 




In the 1980’s, the number of randomized controlled trials exploring possible treatment 
options for children and adolescents with depression and anxiety began to rise steeply.  
 
 
However, a larger amount of clinical trials looking into the safety and efficacy of 
treatment options in depression and anxiety have been directed at adults.  Despite this, 
pharmacologic as well as therapeutic treatment of young people with depression has been 
widespread.  It is unclear whether results from adult populations can, or should, be 
extrapolated to include children and adolescents.  In addition, the effectiveness of some 
of these treatment options, especially for young people, has yet to be established.  One 
recent study [10], for example, found that although clinical trials have proven cognitive-
behavioral therapy to be efficacious in the treatment of youth with depression, 
community clinic treatment of young people with depression has not proven to be as 
beneficial for patients, with results comparable to no treatment at all.  These issues have 
become more controversial given the recent questions surrounding the safety and efficacy 




Many people, children and adults alike, do not seek treatment for mood disorders.  As 
noted by the Surgeon General in the 1999 Report on Mental Health, “nearly two-thirds of 
all people with diagnosable mental disorders do not seek treatment.”  [11] Of those that 
do, many seek care from primary care practitioners rather than specialists in the field.  
One of the most significant reasons for this lack of treatment-seeking and utilization of 
specialists is the role of stigma in mental health care, which the Surgeon General’s office 
reports may be linked with fear of the violence can be associated with mental health 
disorders. [11] However, there may be other issues at play.  One study, for example, 
 
 
found that while the utilization of mental health services in San Francisco’s Chinatown 
was minimal, this was more likely to be due to a decreased level of acculturation, and 
lack of information about available services, than stigma. [12] 
 
The role that demographic factors such as race or ethnicity may play in treatment-seeking 
behavior is somewhat unclear.  In 1987, Sussman et al. [13] found the proportion of 
African-Americans fearing mental health treatment to be 2.5 times higher than White 
patients.  When examining attitudes towards ADHD and its treatment, Bussing et al. 
found that African-American parents of children meeting ADHD criteria were less likely 
to use medical labels than White parents. [14] African-American parents also expected a 
shorter course of treatment.  It has been reported that African-Americans are less likely 
than Caucasians to visit mental health professions. [15]  While there are differences in 
insurance rates between Blacks and Whites, it has been found that the possession of 
above-average mental health coverage increases treatment-seeking among Caucasian 
patients more than in African-Americans. [16] In a study of the Epidemiologic 
Catchment Area Program, Gallo et al. also found that White Americans were 
significantly more likely to have consulted a mental health specialist in the 6 months 
prior to the interview than African-Americans, Hispanics, and other minority groups. [17]  
However, other recent research has stated that Latino patients, while less likely to 
approve of antidepressant medications, are also more likely to support counseling than 
Caucasians or African-Americans. [18]  In a follow-up study to one initially conducted in 
1981, Cooper-Patrick et al. reported that while at baseline African-Americans were 
initially less likely than Caucasians to receive mental health services, use among African-
 
 
Americans patients increased over the 1980’s. [19] By follow-up in the mid 1990’s, 
Black patients were as likely to utilize mental health services offered in general 
practitioner offices as White patients.  While there has been much research on treatment-
seeking behavior in mental health, it is clear that continuing study is called for, especially 
as pertains to children and adolescents.  
 
Health Disparities 
The IOM report on disparities, “Racial and Ethnic Disparities in Health Care,” found that 
many health disparities exist, in a variety of medical specialties.  African-Americans in 
the United States have higher mortality rates.  This is especially striking in the case of 
African-American males as well as in infant mortality, which for Black patients is twice 
that of Caucasians in this country.  A significant difference in infant mortality exists even 
when other socioeconomic factors, such as income, are controlled for.  [15]  It has been 
shown that African-Americans, in particular, suffer from higher rates of various diseases, 
with poorer outcomes.  Black patients also suffer from higher morbidity rates in diabetes 
(three times that of White patients), heart disease (40% higher), HIV/AIDS (seven times 
higher), prostate cancer (twice as high), and even breast cancer, despite the fact that more 
African-American women undergo screening by mammography. [15]  
 
The IOM report also looked into possible explanations for these various differences in 
health outcomes.  The authors examined over 100 studies in the area of health disparities, 
and discovered that even when controlling for other demographic factors such as income, 
age, insurance status and education level, a majority of the studies found that racial and 
 
 
ethnic minorities were less likely to “receive needed services, including clinically 
necessary procedures.” [20].  The report hypothesizes that one possible reason that racial 
and ethnic minorities receive lower quality health care than White patients is due to a 
subconscious racial bias that physicians may possess.  It also cites various studies that, 
for example, have shown that doctors, when presented with the same written description 
of a patient’s case except for the race of the patient, have offered treatment 
recommendations that differed.   
 
Of particular relevance to this review, it has also been found that ethnic minorities 
receive substandard mental health care. [11, 21] In addition, the increased amount of fear 
of mental health treatment amongst African-American adults mentioned earlier [13] is 
likely related to the fact that African-Americans have been found to have increased rates 
of involuntary hospitalization when compared to Caucasian patients with similar 
psychopathology levels. [22] Among young people in particular, African-American 
children have been found to be more likely to have “unmet need3” than Caucasian 
children. [15] Some studies have reported higher rates of certain mental health disorders 
such as obsessive-compulsive disorder and conduct disorder, along with depressive 
symptomology and enuresis, among minority children.  Also of note is that 42% of 
children in foster care have been found to meet DSM-IV criteria for a mental health 
disorder. [23] Minority children are over-represented in the foster care/child welfare 
system. 
 
                                                 
3 Those with documented impairment due to mental illness who have not received mental health care in 
preceding six months. 
 
 
Attitudes toward medicine/research 
Studies have been done relating race and/or ethnicity to attitudes towards the medical 
profession in general, with African-American adults being more likely to distrust doctors 
[24], including those running clinical trials. [25] Black patients are more likely to have 
heard of the Tuskegee syphilis experiment4 than White patients. [25, 26] This lack of 
trust in the medical profession may contribute to researchers experiencing increased 
difficulty when attempting to recruiting minority patients into medical trials, in particular 
when there are no directed attempts at minority outreach.  For adults with depression, 
race/ethnicity, in particular, has been found to be significantly correlated with treatment-
seeking, the acceptability of certain kinds of treatments over others, and also the clinical 
setting in which depressed patients are most likely to seek help.  Minority patients have 
been found to be more likely to visit primary care practitioners or emergency rooms than 
mental health professionals. [27] African-Americans have also been found to be 
significantly more likely to exclusively consult friends and/or family members about 
mental health issues, rather than doctors or other healthcare providers. [27] Attitudes 
towards the health profession in general, and mental health practitioners specifically, may 
affect patients’ decisions about participating in clinical trials, seeking help, or even the 
effectiveness of therapy or other treatments.   
 
NIH Revitalization Act of 1993 
The number of randomized controlled clinical trials testing the efficacy and effectiveness 
of both pharmaceutical and therapeutic treatments is on the rise.  However, the 
                                                 
4 Observational study of syphilis outcomes in which African-American male patients with syphilis were not 




generalizability of these trials, based on demographic factors including race and/or 
ethnicity, is an important issue, one that the United States government as well as the 
National Institutes of Health (NIH) have acknowledged.  This is especially true given the 
existence of a multitude of health disparities, and the lack of clear rationale for these 
inconsistencies in health and health care. 
 
The NIH Revitalization Act, signed into law by President Clinton in 1993, directed the 
National Institutes of Health to create a set of guidelines for the inclusion of women and 
racial/ethnic minorities in clinical research.  The purpose of the proposed guidelines was 
to supplement existing guidelines in four ways; by ensuring that 1) women and racial 
minorities were included in clinical research, 2) cost would not be permissible as a factor 
in excluding women and minorities, 3) the NIH would start and assist in outreach efforts 
for women and minorities in studies, and finally that 4) clinical trials would be 
…designed and carried out in a manner sufficient to provide for valid 
analysis of whether the variables being studied in the trial affect women or 
members of minority groups, as the case may be, differently than other 
subjects in the trial. [28] 
 
The statute also states that the exclusion of women and minorities is only to be allowed 
under certain circumstances, such as when either the health of the participants or the 
purpose of the research deems inclusion unacceptable, or if past research strongly refutes 
the possibility of a difference in outcome or severity due to gender or race. 
 
NIH Guidelines of 1994, Amended 2000 & 2001 
In 1994, the National Institutes of Health published a set of guidelines mandating the 
inclusion of women and minorities in clinical research, as directed by the NIH 
 
 
Revitalization Act of 1993.  Since that time, all clinical research funded by the NIH has 
been required to meet these minimum standards.  In addition to representation of women 
and racial/ethnic minorities in clinical trials, the NIH Guidelines also require each 
research proposal to include a description of outreach programs to recruit these 
underrepresented groups.  However, the “valid analysis” required by the Revitalization 
Act is defined by the NIH as “an unbiased assessment,” [28] including randomization 
into groups and use of unbiased outcomes evaluation and statistical analysis among 
groups.  The Guidelines do not require every NIH - funded clinical trial to have the 
statistical power necessary to explore possible differences due to gender or race/ethnicity.  
They also report that analyses should look for a “significant difference,” of public health 
or clinical importance, rather than a “statistically significant difference.” [28] 
 
The two later amendments to the NIH Guidelines, in 2000 and 2001 [29], were primarily 
created to redefine the term “clinical trial” as well as the process of data collection on 
race and ethnicity.  Specifically, the NIH now mandates the use of racial and ethnic 
categories as defined by the United States Office of Management and Budget.  
Researchers are required to first ask participants to classify their ethnicity into one of two 
categories: 1) Hispanic or Latino and 2) Not Hispanic or Latino.  Participants should then 
have the option of categorizing their race into one or more groups. These include: 
American Indian/Alaska Native, Asian, Black/African-American, Native Hawaiian/Other 





Race & Ethnicity: Definitions & Stress 
It has been maintained that the NIH Guidelines described above were created in an 
attempt to ensure that the science behind clinical trials is generalizeable to a larger 
population, rather than due to political reasons or popular opinion. [30] It can be argued 
that the use of race and ethnicity in clinical trials is important because double-blind 
studies, in particular, may offer one of the few ways to display any potential ethnic and/or 
cultural differences in mental illness and treatment without bias, or at least with 
significantly decreased bias. However, along with a mandate to produce studies 
containing larger numbers of minority subjects comes the question of the definition of 
both race and ethnicity, as well as how to best approach analyses involving these 
variables.  In a 1996 special supplement, the Journal of Consulting & Clinical 
Psychology published a number of articles regarding the implementation of the NIH 
Guidelines, including two that addressed the concepts behind demographic factors such 
as race and ethnicity. [31, 32] Beutler et al., in a review of articles published in three 
journals between 1970 and 1993, reported that demographic variables such as race, 
ethnicity, sex, gender, and age, were “not used consistently and lack empirical and 
conceptual validity.” [31] They argue that these should be considered as constructs rather 
than immutable characteristics, and as such, investigators should report the definitions 
and explain the use of each term in clinical research.  In addition, they specify that the 
word ‘ethnicity’ should be used in lieu of ‘race’ whenever the implication of a cultural vs. 




The potential for misuse is often cited as reason to be wary of considering race or 
ethnicity in clinical trials.  Science has a history of being used as justification for the 
mistreatment and continued oppression of people of color. [33, 34] One potential reason 
for the lack of minority representation in clinical studies and the lack of analysis of 
potential effects of race or ethnicity is that investigators may lack experience with multi-
cultural or underrepresented populations.  As such, many may be wary of attempting to 
interpret differences attributed to ethnicity, or believe that multiple different hypotheses 
are required in order to address each racial or ethnic category. [32] When investigating 
potential differences in outcomes based on ethnicity, however, an important consideration 
is the role that minority status5 may play in results.  Past research has found that among 
ethnic minorities in the United States, life experiences are shaped by minority status. [35] 
in [32] Because of this, it may be important for clinical research investigators to include a 
set of questions, or tools, to assess such issues including the amount stress encountered 
by participants.  The importance of this is highlighted by the fact that 60% to 70% of 
adults who suffer from depression have been found to have undergone one or more 
losses, or other life events rated as severely stressful, in the one year preceding onset of 
the depressive episode. [3] 
 
Moderators/Secondary Analyses 
A moderator is defined as a variable that precedes treatment and is unchanging, at least 
during the course of treatment.  It has the potential to affect treatment outcomes, but is 
uncorrelated to treatment. [36] Moderators are essential when attempting to assess the 
                                                 
5 Defined by Alvidrez et al. as: “the designation of members of particular groups as inappropriate, 
unwelcome, or inferior, that justifies and perpetuates their systematic exclusion from full participation in 
society or access to its rewards” 
 
 
effectiveness of a particular treatment option, for example, as they can help identify 
specific populations or sub-populations that may experience different treatment 
outcomes.  They “specify for whom and under what conditions an intervention works.” 
[36]  Mediators, on the other hand, may change during treatment (such as treatment 
adherence or dosage), and have been shown to have a role in determining the mechanism 
of action of treatments. [36, 37] The terms mediator and moderator are mutually 
exclusive.  The classification of a variable as a moderator or mediator is done through 
secondary analyses, which increases the risk of type II errors while remaining at risk for 
type I errors. [37] Researchers can determine which variables to explore as potential 
moderators or mediators based on previous data or theory; these analyses are considered 
to be methods of creating new hypotheses rather than testing them. [36] In addition, as 
opposed to other types of research, the effect size is prioritized over the P value.  A 
moderate or large effect size points to the possibility of clinical differences that were 
unable to reach significance due to limited power.  Predictors are related to treatment 
results, but in a non-specific way: they are not linked to treatment assignment, and are 
uncontrolled. [37] 
 
STATEMENT OF PURPOSE/HYPOTHESIS 
Beginning with the assumption (required by the NIH) that racial diversity is important to 
the generalizability of clinical trial outcomes, I hypothesize that all pediatric depression 
and anxiety clinical trials will (1) include specific minority outreach plans as part of 
recruitment; (2) include data on minority participation in the sample description; and (3), 
 
 
include a moderator analysis specifically devoted to race/ethnicity.  As a comparison, 
race will be compared to gender and SES, two other important demographic variables.   
 
There is more work to be done in the field of treatment for child & adolescent mood 
disorders.  It has been found that some pharmacological and therapy-based treatments can 
be efficacious when treating youth, but it becomes important to design such treatments to 
be as effective as possible.  While generalizations and stereotypes can be dangerous, 
differing beliefs about treatment may require physicians to better design outreach and 
treatment methods to suit the particular population(s) with which they are working 
(which may or may not differ based on demographic variables such as age, 
socioeconomic status, and race).  The aim of this literature review is to consider the trials 
that have already been done in this area (reviewing the use of these demographic factors), 
and define research areas of need in this field.  The broad goal is to ensure that prevention 




Published randomized controlled trials on the treatment of child and adolescent 
depressive and anxiety disorders from 1994 through December 2005 were identified 
using the Medline and PsychINFO databases.  Search terms included depression, 
dysthmia, bipolar, anxiety, separation anxiety, selective mutism, panic disorder, phobia, 
child, and adolescent.  Psychosocial and psychopharmacological treatment studies that 
employed a control or a comparison condition were evaluable.  Medline searches were 
 
 
limited to the English language, with Randomized Controlled Trial as the publication 
type, and to All Infant (birth to 23 months), Pre-School Child (2-5 years), Child (6-12 
years), or Adolescent (13-18 years) for age.  Because of the inclusion of age 18 under the 
Adolescent group in Medline, many adult studies were recovered.  These were excluded.  
PsychINFO searches were also limited to the English language, with Clinical Trial as the 
Form/Content Type, and Childhood (birth-12 years) or Adolescence (13-17 years).  
Systematic reviews in peer-reviewed journals and the reference lists of identified trials 
were used to retrieve additional articles.  Studies conducted entirely or in part (i.e. one 
site of a multi-site study) outside of the United States of America6 were excluded due to 
the use of US Census data as a comparison for racial representation.  Those dealing with 
Obsessive-Compulsive Disorder, Post-Traumatic Stress Disorder, Tourrette’s Syndrome, 
and Trichotillomania were also excluded.  Follow-up studies of randomized controlled 
trials were included when they themselves were classified as RCT’s.  However, to ensure 
that no information was replicated, these follow-up studies were not factored into reviews 
of recruitment strategies nor into the analysis of representation unless such information 
was excluded from the original trial.  In this case, the information from the first follow-up 
study to report recruitment/demographic data was utilized. 
 
The 37 original trials and 13 follow-up studies identified (See Tables 1 and 2) were then 
reviewed for the extent to which race/ethnicity and other demographic factors were 1) 
factored into recruitment strategies; 2) represented in the trial samples; and 3) included in 
moderator analyses to determine the extent to which they may influence trial outcomes.  
When possible, the treatment of race, gender, and socioeconomic status as demographic 
                                                 
6 This includes the 50 states and the District of Columbia, but not Puerto Rico 
 
 
variables and potential moderators were compared.  When looking at overall trends, we 
have combined each individual minority grouping into one category, given the small 
number of participants in each group. 
 
Census Data 
US Census Data was obtained from the US Census website <factfinder.census.gov>.   
Inter-census population estimates were also obtained from this website.  Both the 1990 
and 2000 US Census (as well as population estimates) distinguish between race and 
ethnicity; all participants were asked to report their race as well as whether or not they 
considered themselves to be of Hispanic origin (Spanish, Hispanic, or Latino).  In the 
1990 Census, respondents were asked to identify their race within one of five categories: 
“White,” “Black or African American,” “American Indian and Alaska Native,” “Asian,” 
and “Native Hawaiian and Other Pacific Islander.”  Of note, the 2000 Census included a 
sixth grouping, “Some other race,” and also allowed each participant to select more than 
one of these six categories when describing own race.  Despite this, 98% of people 
reported only one race.  97% of respondents who only reported themselves as “Some 
other race,” are of Hispanic origin. [38]  
 
When reporting Census information from 2000 or afterwards, we use “one race alone” 
responses as an estimate for racial representation in the United States, with the 
understanding that while this does not take into account ~2% of respondents, it better 
allows for comparison across the years given that earlier respondents were not given the 
option of choosing more than one racial category.  Specifically, since NIH guidelines 
 
 
include the use of Hispanic/Latino as a “minority group”, we use the “one race, not 
Hispanic” data for the racial categories described above, and use “Hispanic, any race” 




One study [39], 2.7% of the total number of original trials, did not describe recruitment 
methods used.  
 
The majority of studies (78.4%) [40-68] reported that patients were recruited through 
school referrals, media advertisements, referrals from health care providers, or a 
combination of these three.  Seven (18.9%) [69-75],  however, differed in their approach.  
Two [69, 72] recruited patients from consecutive inpatient admissions for depression and 
bipolar disorder.  These were the only trials in which participants were not recruited as 
outpatients.  In fact, many of the reviewed studies included recent or current inpatient 
admission as part of their exclusion criteria.   
 
The remaining five trials [70, 71, 73-75] instead screened out eligible participants from 
larger previously defined populations (such as students in particular schools or HMO 
members) that were not self-referred or referred by others.  Four of these trials [34, 70, 
73, 75] began with one or more schools, offering screening tests to discover potential 
subjects and then randomizing identified students into treatment groups.  Thompson et al 
investigated suicide prevention methods by initially identifying students deemed at-risk 
 
 
for dropping out of school from seven urban high schools in two school districts in the 
Pacific Northwest, based on various criteria such as attendance and academic 
performance.  They then offered screening specific for suicide risk.  While all four high 
schools in one district were included, only three in the second district were selected.  This 
decision was based on “their geographic and demographic representation of that district’s 
10 high schools.”  Clarke et al. [70], Lamb et al. [73], and Weisz et al. [75] used a similar 
strategy, identifying students with depression or “depressive symptomology” [73] from a 
rural high school [73], 3 suburban high schools[70], and three elementary schools [75].  
While the choice of high schools in Thompson et al was at partially explained, none of 
the three other studies offered a comparison of their schools’ racial composition to that of 
the geographic area in which they are located. 
  
Clarke et al. [71], on the other hand, searched for depressed parents and children from an 
initial sample of about 410,000 patient records from a Health Maintenance Organization 
previously shown to be somewhat representative of the local population.  They ended 
with 88 participants. 
 
Two studies, recruiting from outpatient clinics, specifically stated that they did so 
“without regard to race, gender, or ethnicity.” [48, 68] In a follow-up article to the TADS 
study, however, it is reported that part of the selection process for sites was based on the 
“demographic composition” at the clinics. [76] None of the trials reviewed revealed 
explicit attempts at recruiting women or minorities into the studies, although in both 
studies by Mufson et al. [55, 67] the population was exclusively comprised of adolescents 
 
 
referred to school-based health clinics in New York City, meaning that participants were 
limited to students at those particular schools.  The studies referred to the fact that the 
schools were located in “urban, impoverished areas.” [67] 
 
Representation 
Six of the thirty-seven original studies (16.2%) did not report race or ethnicity in any way 
(See Table 3).  Of these, only one [59] had at least one follow-up RCT published [77] in 
which the racial composition of participants was reported. Of the thirteen follow-up 
studies themselves, five [78-82] did not report the representation of different racial 
categories in the study population.  However, all of these did have race reported in either 
the original study or another follow-up series.  The remaining eight reported race in some 
way. [37, 76, 77, 83-87] 
  
Ten of the initial studies (27.0%) failed to describe the specific race/ethnicity of 
participants, instead forming two groupings: one comprised of Caucasians and the other 
of ‘minorities’ or ‘other.’  While two of these [45, 46] had subsequent follow-ups 
published, none of the seven follow-up trials included more detailed information.   
 
Four studies [55, 56, 67, 74], or 10.8% of the total, reported equal or greater numbers of 
minority participants as compared to Caucasians.  Two studies [41, 85], 5.4%, reported 




Overall, 3330 children and adolescents participated in these thirty-seven original clinical 
trials.  Of these, 3082, or 92.6% of the participants, took part in studies reporting race 
and/or ethnicity.  The majority of these young people described themselves as Caucasian 
(n=2213, 66.5% of the total, 71.8% of those studies reporting race).  288 (8.6% of total, 
9.3% of reporters), were African-American; 277 (8.3% total, 9.0% reporters) were 
Latino; 89 (2.7% of total, 2.9% of reporters) were Asian/Pacific Islander, 18 (0.5% of 
total, 0.6% of responders) were Native American, and 6 (0.2% of total & reporters) 
classified themselves as “Mixed-Race”.  In addition, 190 (5.7% total, 6.2% reporters ) 
were either grouped into an “other” category in those studies specifying specific 
races/ethnicities, or were categorized as “minorities” in those studies choosing not to 
specify race other than Caucasian.  248 of the 3330 total participants (7.4%) contributed 
to those studies not reporting race/ethnicity in any way in the original publication.  Of 
these, however, 63 were participants in the Bernstein et al. [59] trial, for which a follow-
up study detailing demographic data was published. [77]  Therefore, the race and/or 
ethnicity was not reported for 185 children and adolescents (5.6%) contributing to 























Figure 1. Minority Representation in Original Trials Reviewed 
 
 
The large (n > 100) studies, of which there were nine, accounted for over half (59.8%) of 
the total participants.  A greater percentage of these participants (70.9%) classified 
themselves as Caucasian, African-Americans (12.1%), Asian (4.2%), and Native 
American (0.9%).  However, a lower percentage of subjects in the large studies consider 
themselves to be Latino (6.1%) and Mixed-Race (0%).  As compared to all  original 
studies, about the same proportion (5.8%) of participants were classified as minorities, or 
considered themselves “Other.” 
 
There were a larger number of studies conducted in the area of depression/bipolar (n=22) 
than anxiety/phobic disorders (n=15).  In addition, there were far more participants 
(n=2336 vs. 994).  28.2% of participants in depression studies, and 21.1% of anxiety trial 
subjects, classified themselves as minorities.  11.2% of the subjects’ race went unreported 
in anxiety trials, vs. 5.9% in depression trials.  In studies of psychotherapy interventions 
only (21 studies with 2323 total participants), 29.3% of the children and adolescents were 
minorities.  Race was unreported for 5.6% of them.  In trials that included at least one 
branch testing pharmacotherapeutic options (16 studies, n=1007), race was unreported for 
14.3% of subjects.  18.8% were minorities. 
 
According to the 2000 US Census data, 69.4% of the US population defines themselves 
as White or Caucasian (not Hispanic), 11.8% as Black or African-American, 12.5% as 
Hispanic or Latino, and 3.7% as Asian, 0.6% as American Indian or Alaska Native, and 
0.1% as Native Hawaiian or Pacific Islander.  However, the yearly population estimates 
 
 
from 1994 through 2005 show a fairly steady, if small, upward trend in terms of the 
percentage of people classifying themselves as racial/ethnic minorities. (Figure 3) 
 
There are three years, 1996, 1999, and 2001, in which the percentage of minorities 
participating in reviewed clinical trials was greater than the percentage classifying 
themselves as minorities in US Census estimations.  In 1996, only two original trials were 
reviewed, the larger of which (n=151) had a relatively large proportion of minorities, 
about one third. The smaller study (n=31) consisted of about one quarter.  In 1999, the 
results were significantly affected by the fact that two of the four studies reviewed from 
that year had greater numbers of minority participants than Caucasian participants.  
Interestingly, one study of the four did not report race at all, and the remaining study 
from 1999 was almost 40% minority.  Similarly, in 2001, study with the largest sample 
size reviewed, n=460, had a greater proportion of minority subjects than Caucasian 
subjects. 
 
Although both the number of randomized, double-blind trials in the field of child and 
adolescent psychiatry as well as minority participation in these trials have generally 
increased since 1994, there does not seem to be an obvious trend in minority 
representation when studies are examined by year.  This remains true when confidence 
intervals are taken into account. (see Figure 2)  Of the eleven years examined in this 
review, only in four years did the proportion of minority participants approach or exceed 
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Figure 2. Minority Representation by Year (as Compared to US Census Data).  UCI: Upper Confidence 
Interval.  LCI: Lower Confidence Interval 
Moderator Analyses 
Of the original studies reviewed, nine made no mention of whether there were pre-
treatment or randomization differences based on demographic variables. [41, 43, 45, 51, 
53, 54, 61, 71, 75] Five, while discussing other demographic variables such as sex and 
age, did not include race/ethnicity. [40, 46, 50, 70, 73] Twelve used general phrases such 
as ‘no differences between treatment groups based on demographic variables” without 
explicitly mentioning race.  Of these studies, two did not report the race of the 
participants. [48, 59] Eleven discussed race or ethnicity, primarily in order to ensure the 
lack of pretreatment differences across groups, and/or between completers and non-
completers.  Of these, Treadwell and Kendall reported an increased number of African-
Americans in the control group, and randomized to the wait list.  Birmaher et al. 
commented that there were no African-American males in the study population. [69]  Of 
note, every original study reviewed reported patient sex or gender along with age.  One 
 
 
study was noted to be entirely comprised of females; race was unreported in the trial. [61]  
Fifteen reported some form of socioeconomic status (SES) or income.   
 
Eleven original studies did not otherwise mention race or ethnicity in the “Results” or 
“Discussion” (or equivalent) sections at all.  Eight pointed out that more ethnically 
diverse samples were necessary, or cited “ungeneralizability” as a study weakness.  
Interestingly, the authors of one of these trials discussed that the study might not be 
applicable to the larger population due to the large numbers of Latino females in the 
sample. [55] Five either explored the possibility of race or ethnicity having an interaction 
or moderating effect, and/or discussed race or ethnicity as it pertained to treatment 
outcomes. [42, 44, 47, 56, 75] Of these, three (8.1%) explicitly explored the possibility of 
ethnicity as a moderator through analysis of variance (ANOVA) testing; it was found to 
have no moderating role in any.  The other two point out that “comparable effectiveness” 
[47]is suggested across demographic lines.  
 
Of the thirteen follow-up studies, six considered ethnicity when attempting to determine 
whether there were randomization or completer/non-completer differences.  Three 
(23.1%) were written to look for possible moderators and mediators in depression [81, 
85] and anxiety [37].  In all three analyses, no demographic moderators were found.  In 
the RUPP article, however, race/ethnicity was initially found to have an effect size of 
0.47 (with 0.5 being considered a moderate effect size).    Further investigation showed 
that neither 3-way (p=0.07) nor 2-way (p=0.33) interactions were statistically significant.  
In addition, the TADS follow-up study looked at demographic characteristics, comparing 
 
 
their population to previous work.  The authors specifically mentioned the possibility of 





Few trials demonstrate any directed attempts during recruitment to ensure racial/ethnic 
diversity.  In those trials that screened out participants from a larger population, the 
choice of school, hospital, or HMO location proved to affect the diversity of the study 
sample population.  For instance, in the two Mufson et al studies [55, 67], school clinics 
located within public schools in New York City were used as the site of the research, 
resulting in a high percentage of minorities, particularly Latinos.  In the Thompson et al. 
study, the location of the seven urban high schools examined, in the Pacific Northwest, 
allowed for a greater number of minorities, particularly Asian/Pacific Islander and Native 
American.  The study noted that the contributing schools had minority representations 
ranging from 34% to 60%.  On the other hand, the Clarke et al. [71] trial noted that it 
screened the entire population of an HMO, also located in the northwest, that was 
representative of the surrounding area.  Despite this, the final result was a sample 90% of 
which was Caucasian.  It was not noted whether or not the HMO was located in an urban 
or rural area.  Both studies that recruited directly from inpatient hospitalization ended 
with similar numbers of minority representation; Birmaher et al 1998 had a minority 
representation of 11.1%, while DelBello et al. was comprised of 16.7% minority 
participants.  Both fell below the average for all studies reviewed.  Of note, one multi-site 
 
 
trial [68] documented, in a follow-up study also reviewed, that demographic make-up of 
potential sites played a role in their selection. 
 
It is important to investigate the trials that ended with a greater number of minority 
participants, as well as those that ended with none, to assess whether recruitment 
methodology may have played a part in representation outcomes.  Again, four studies had 
equal or greater numbers of minorities.  Of these, only Silverman et al. 1999 utilized the 
most common form of recruitment, referrals from a variety of sources including schools 
and health professionals.  The remaining three [55, 67, 74] recruited from school-based 
clinics based in urban public schools, greatly affecting the potential trial population from 
the start.  Given the likelihood of any public school to approach or exceed minority 
representation on a local level, one feasible option for investigators seeking to augment 
the proportion of minorities in their trial seems to be to increase involvement .  However, 
there are drawbacks as well, such as the possible restrictions placed on research by school 
districts. 
 
The only trial reviewed with 0% minority representation was Graae et al. 1994, a study 
that reported the use of clinic and school sources along with newspaper ads as 
recruitment methods.  Of the ten reviewed trials that utilized advertisements in any way, 
four did not report race/ethnicity.  Overall, 196 of the 1036 total participants (18.9%) in 
these studies classified themselves as minorities.  Of the three trials that reported only 
using methods of advertisements7 as recruitment tools, none reported the race of their 
                                                 
7 Local ads and/or announcements sent to schools/clinics 
 
 
subjects.  Three studies used advertisements as part of a large variety8 of recruitment 
methods; in these, 27.0% of  the participants were minorities.  Given the differences in 
attitudes toward medicine and medical research experienced by persons of different 
ethnic backgrounds, it is possible that ad placement, while potentially reaching a great 
number of people, may be too impersonal a method to sufficiently reach a minority 
population.  Interestingly, one study [45] reported that participants recruited via clinic 
referral were less likely to respond to psychotherapy than those recruited by 
advertisement.  This was attributed to differences in hopelessness scores.  The trial did 
not indicate whether method of recruitment was associated with race or ethnicity in any 
way.   
 
As mentioned above, there are numerous examples of the ways in which race can play a 
role in the amount of trust a prospective study participant has in medical researchers 
and/or medical trials, and a number of historical reasons for this disparity.  Such a lack of 
trust may make it significantly more difficult for investigators to obtain ethnically diverse 
samples, which is vital when attempting to tease out the possible role that race may play 
in treatment outcomes.  However, this difficulty cannot be an excuse, especially given the 
emphasis in the NIH Guidelines on minority outreach methodology.  Targeted recruiting 
methods exist; it is the role of researchers to ensure that their samples are representative.  
Training and increased education on this subject are essential.  The NIH has published an 
“Outreach Notebook” as a tool to assist researchers with recruitment of minority 
participants. [88] In addition, there have been other series, such as the Journal of 
Consulting and Clinical Psychology’s (JCCP) post-NIH Guideline supplemental issue in 
                                                 
8 Four or more different methods used, including advertisements 
 
 
1996.  The articles included addressed a variety of issues surrounding the guidelines and 
their implementation, including the importance of recruitment methods.   
 
In one article, the outreach methods utilized in a sizeable study of psychiatric inpatients 
in a low-income, urban area are described. [34] The authors describe a four-pronged 
approach to the recruitment of African-Americans with schizophrenia or mood disorders.  
Through a combination of a community partnership with a local mental health clinic, 
emphasis on interviewer selection and interviewer training, and an exploration of the role 
of cultural sensitivity through an assessment of ethnic matching9, they were able to 
recruit a sizeable population of African-American patients.  Of note, they found that 
ethnic matching did not affect refusal or completion rates; patients were more likely to 
refuse or drop out based on type of mental illness. [34] This is positive news for 
investigators interested in recruiting greater numbers of minority participants, particularly 
since it seems possible that the focus on interviewer training may have helped to 
overcome potential barriers based on race or ethnicity.  However, it may also be valuable 
to recruit an increased number of minority researchers, given the fact that both the IOM 
and Surgeon General’s Report state that minority medical professionals are more likely to 
work in areas comprised of minorities, and that in general, patient trust may be increased 
with doctors or researchers of the same racial/ethnic background. 
 
Representation 
Despite the fact that the majority do report in some way the racial/ethnic breakdown of 
their sample population, approaches to this process, as well as the level of specificity, 
                                                 
9 Matching recruiter/interviewer and patient by race, ethnicity, cultural background, or a combination 
 
 
varies from study to study.  The majority of patients participating in these studies are 
classified as Caucasian.  Overall percentages of African-Americans, Latinos/Hispanics, 
and Asian/Pacific Islanders participating in trial samples are lower than those reported in 
the US population as of the 2000 Census.  While the proportion of Native Americans 
participating in these studies is equal to the proportion in the United States, only one 
reviewed trial  (Thompson et al.) included any Native American participants.  Looking at 
yearly US population estimates by race and ethnicity since 1994, there has been a small 
but steady increase in the percentage of the US population that is comprised of people 
self-identifying as minorities.  In 1994, 26.0% of the US population classified themselves 
as minorities, while in 2004 that number was 31.1%.   
 
This rise is primarily due to the proportion of Hispanics and Latinos in the country, which 
increased from 10% in 1994 to 14.2% in 2004.  Given this fact, it becomes even more 
important consider the role of culture and language in treatment outcomes research.  
Many reviewed studies included language other than English as an exclusion factor, 
which may have decreased the number of minority patients able to participate, 
particularly in the Latino and/or Asian categories.  The Spanish language is spoken by 
approximately 30 million US citizens over the age of 5. [89] The United States hosts the 
5th largest Spanish-speaking community in the world. [89] One recent study not included 
in this review,10 by Rossello and Bernal, did begin to address some of these issues. [90] 
With a study population that was 100% Hispanic/Latino, and Spanish-language 
interventions available, the trial referenced their use of culturally sensitive therapy.  One 
reviewed study [67] allowed primarily Spanish-speaking students to participate in two 
                                                 
10 Due to its location in Puerto Rico 
 
 
sites (out of five); two others mentioned and briefly described their use of culturally 
sensitive therapy. [56, 57] Of note, these two trials had study populations comprised of 
44.5% minorities, much higher than that of the US population.  While shown to be 
effective in a number of trials, cognitive behavioral therapy (CBT) has also been shown 
to less efficacious in community samples than in trials.  (Weersing and Weisz 2002) The 
inclusion of greater numbers of minority participants in studies, along with the increased 
use of ‘culturally sensitive’ therapy, may serve to better allow the transfer of CBT and 
other therapies in particular from the controlled trial to the clinic. 
 
Moderator Analyses 
Three of the original studies reviewed, 8.1%, specifically included ethnicity as a potential 
moderator as part of their analyses.  In addition, there were three follow-up studies (23%) 
designed to search out the role of various demographic and other variables as moderators 
and mediators.  Among the other studies that explored possible effects of race or ethnicity 
on treatment outcome, many discussed trends rather than reporting means.  One follow-
up study, citing their large and diverse sample size, did discuss future moderator and 
mediator analysis. [76] However, the majority of studies reviewed do not have the sample 
sizes or minority representation required to accurately assess the possibility of race or 
ethnicity as a moderator. 
 
Limitations 
Due to the variety of disorders and treatment options reviewed, a meta-analysis was 
unable to be done.  Instead, a literature review, a less statistically rigorous method, was 
 
 
performed on these trials.  Because of this, it is impossible to estimate the role that 
race/ethnicity may play in child and adolescent depression and anxiety based on current 
outcomes research.  Rather, this review serves to look at the research being done in this 
area, with an emphasis on the way that race and ethnicity are incorporated into outreach 
strategies, reporting methods, and analysis.    
 
The methods used to identify trials, including Medline and PsychInfo searches as well as 
reviewing reference lists, may not have been all-inclusive.  Some trials may have been 
missed.  In addition, some of the exclusion criteria used in this review, particularly the 
limitation to those studies performed entirely within the United States, served to 
eliminate some important large and/or multi-site studies, such as the Rosselló and Bernal 
trial mentioned above as well as a 2004 multi-center trial investigating the use of 
paroxetine in Social Anxiety Disorder (Wagner et al.), to name only a few.  Another 
important exclusion criterion was disorders such as OCD and PTSD, which may have 
overlooked trials that did include considerable numbers of minority participants and/or 
performed moderator analyses using race and ethnicity. 
 
Future Research Needs 
Based on this review, it seems clear that additional work needs to be done in order to 
correctly assess the existence of a relationship between race/ethnicity and treatment 
outcomes in child and adolescent trials in depression and anxiety.  Given the differences 
between study populations and the US population with regard to race and ethnicity, the 
generalizability of many of the trials reviewed is uncertain.  It is also unclear that 
 
 
outreach methods currently being used are sufficient to recruit large numbers of minority 
participants.  It is possible that more training is necessary for investigators in order to 
achieve adequate sample sizes as well as report accurately using NIH guidelines.  Once 
this is achieved, it will become possible for a greater number of studies to investigate the 




There has been significant improvement in the inclusion of minorities in randomized 
controlled trials in the field of child and adolescent depression.  However, minority 
representation in trials reviewed between 1994 and 2005 (inclusive) still lags behind US 
Census Data, both in average and also when compared on a yearly basis.  There is no 
apparent trend when minority trials are aggregated by year; that is, as opposed to US 
Census data over the past 11 years, there has been no steady increase or decrease of 
minority representation in these clinical trials.  Rather, it seems that some trials, 
particularly the larger multi-site studies along with those that are comprised of over 50% 
minority participants, have sizeable effects on the percentage of minority participants in a 
given year.  Inclusion of minorities in clinical trials may be positively influenced by a 
shift in the focus of recruitment methods.  The more universal consideration of 
demographic makeup during clinical site selection may prove to increase the number of 
minority participants in RCT’s.  Also, additional investigator training and/or sharing of 
“best practices” may encourage the use of targeted recruitment methods.  As the 
proportion of minority subjects in child and adolescent depression and anxiety trials 
 
 
increases, it will become possible for moderator analyses to be performed, so as to 
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Table 1. Original RCT’s Reviewed (1994-2005) 
 
Year Author(s) Title Disorder Treatment 
1994 Black and Uhde 




1994 Graae et al Clonazepam in Childhood Anxiety Disorders Anxiety Clonazepam 
1994 Kendall et al. 
Treating Anxiety Disorders in Children: Results of a Randomized 
Clinical Trial Anxiety CBT 
1995 Clarke et al. 
Targeted Prevention of Unipolar Depressive Disorder in an At-Risk 
Sample of High School Adolescents: A Randomized Trial of  a Group 
Cognitive Intervention Depression GCBT 
1996 Kye et al 
A Randomized, Controlled Trial of Amitriptyline in the Acute 




Self-Talk in Youth With Anxiety Disorders: States of Mind, Content 
Specificity, and Treatment Outcome Anxiety CBT 
1997 Brent et al 
A Clinical Psychotherapy Trial for Adolescent Depression Comparing 
Cognitive, Family, and Supportive Therapy 
Major 
Depression CBT, SBFT, NST 
1997 Emslie et al 
A Double-Blind, Randomized, Placebo-Controlled Trial of Fluoxetine 
in Children and Adolescents with Depression Depression Fluoxetine 
1997 Kendall et al 
Therapy for Youths with Anxiety Disorders: A Second Randomized 
Clinical Trial Anxiety CBT 
1997 Sallee et al 
Pulse Intravenous Clomipramine for Depressed Adolescents: Double-
Blind, Controlled Trial Depression Clomipramine 
1997 Weisz et al 
Brief Treatment of Mild-to-Moderate Child Depression Using Primary 
and Secondary Control Enhancement Training Depression 
Prim & Sec Control 
Enhancement Training 
1998 Ackerson et al 
Cognitive Bibliotherapy for Mild and Moderate Adolescent 
Depressive Symptomatology Depression Cognitive Bibliotherapy 
1998 Birmaher et al 
Randomized, Controlled Trial of Amitriptyline Versus Placebo for 





1998 Geller et al 
Double-Blind and Placebo-Controlled Study of Lithium for 
Adolescent Bipolar Disorders with Secondary Substance Dependency Bipolar Lithium 
1998 Geller et al 
Lithium for Prepubertal Depressed Children with Family History 
Predictors of Future Bipolarity: A Double-Blind, Placebo-Controlled 
Study Depression Lithium 
1998 Klein et al 
Adolescent Depression: Controlled Desipramine Treatment and 
Atypical Features Depression Desipramine 
1998 Lamb et al School-Based Intervention to Promote Coping in Rural Teens Depression School-based CBT 
1998 Last et al Cognitive-Behavioral Treatment of School Phobia 
School 
Refusal CBT 
1999 Clarke et al 
Cognitive-Behavioral Treatment of Adolescent Depression: Efficacy 
of Acute Group Treatment and Booster Sessions Depression 
GCBT, GCBT + parent group; + 
"Booster" sessions 
1999 Mufson et al Efficacy of Interpersonal Psychotherpay for Depressed Adolescents Depression IPT 
1999 Silverman et al 
Treating Anxiety Disorders in Children With Group Cognitive-
Behavioral Therapy: A Randomized Clinical Trial Anxiety GCBT 
1999 Silverman et al 
Contingency Management, Self-Control, and Education Support in the 




cont. management, cog. self-
control, ed. support 
2000 Beidel et al Behavioral Treatment of Childhood Social Phobia Social Phobia Behavioral Treatment 
2000 Bernstein et al 







Group and Individual Cognitive-Behavioral Treatments for Youth 
with Anxiety Disorders: A randomized Clinical Trial Anxiety CBT, CBGT 
2000 Hayward et al 
Cognitive-Behavioral Group Therapy for Social Phobia in Female 
Adolescnts: Results of a Pilot Study Social Phobia CBGT 
2001 Kendall et al Comorbidity in Childood Anxiety Disorders and Treatment Outcome Anxiety CBT (Comorbidity) 
2001 RUPP Group 
Fluvoxamine for the Treatment of Anxiety Disorders in Children and 
Adolescents Anxiety Fluvoxamine 
2001 Rynn et al 
Placebo-Controlled Trial of Sertraline in the Treatment of Children 
with Generalized Anxiety Disorder Anxiety Sertraline 
 
 
2001 Thompson et al 
Evaluation of Indicated Suicide Risk Prevention Approaches for 
Potential High School Dropouts Suicide CARE, CAST 
2002 Clarke et al 
Group Cognitive-Behavioral Treatment for Depressed Adolescent 
Offspring of Depressed Parents in a Health Maintenance Organization Depression GCBT vs usual care 
2002 DelBello et al 
A Double-Blind, Randomized, Placebo-Controlled Trial of Quetiapine 
as Adjunctive Treatment for Adolescent Mania Bipolar Quetiapine 
2002 Emslie et al 
Fluoxetine for Acute Treatment of Depression in Children and 
Adolescents: A Placebo-Controlled, Randomized Clinical Trial Depression Fluoxetine 
2003 Birmaher et al Fluoxetine for the Treatment of Childhood Anxiety Disorders Anxiety Fluoxetine 
2004 Mufson et al 
A Randomized Effectiveness Trial of Interpersonal Psychotherapy for 
Depressed Adolescents Depression IPT 
2004 TADS Team 
Fluoxetine, Cognitive-Behavioral Therapy, and Their Combination for 
Adolescents With Depression Depression CBT, Fluoxetine, Both 
2004 Wagner et al 
A Randomized, Placebo-Controlled Trial of Citalopram for the 





Table 2. Follow-up RCT’s Reviewed (1994-2005) 
 
Year Author(s) Title Disorder Treatment 
Original 
Study 
1998 Brent et al 
Predictors of Treatment Efficacy in a Clinical Trial of Three 
Psychosocial Treatments for Adolescent Depression Depression 
Psychosocial 
Treatments Brent 1997 
1998 Emslie et al 
Fluoxetine in Child and Adolescent Depression: Acute and 
Maintenance Treatment Depression Fluoxetine Emslie 1997 
1998 Renaud et al 
Rapid Response to Psychosocial Treatment for Adolescent 
Depression: A Two-Year Follow-up Depression 
Psychosocial 
Treatments Brent 1997 
1999 Brent et al 
A Clinical Trial for Adolescent Depression: Predictors of 
Additional Treatment in the Acute and Follow-up Phases of the 




Prediction of response to Fluoxetine and placebo in children and 
adolescents with major depression: a hypothesis generating study Depression Fluoxetine Emslie 1997 
2000 
Bernstein et 








Clinical Outcome After short-Term Psychotherapy for 
Adolescents With Major Depressive Disorder Depression Psychotherapy Brent 1997 
2000 Kolko et al 
Cognitive and Family Therapies for Adolescent Depression: 
Treatment Specificity, Mediation, and Moderation Depression CBT, SBFT, NST Brent 1997 
2003 Layne et al 
Predictors of Treatment Response in Anxious-Depressed 
Adolescents with School Refusal 
School 
Refusal 







Searching for Moderators and Mediators of Pharmacological 
Treatment Effects in Children and Adolescents with Anxiety 
Disorders Anxiety Fluvoxamine RUPP 2001 
2004 Emslie et al 
Fluoxetine Treatment for Prevention of Relapse of Depression in 
Children and Adolescents: A Double-Blind, Placebo-Controlled 
Study Depression Fluoxetine Emslie 2002 
 
 
2004 Kendall et al 
Child Anxiety Treatment: Outcomes in Adolescents and Impact 




The Treatment for Adolescents With Depression Study (TADS): 




Table 3. Minority Representation (by %) in Original Trials Reviewed 
 























Mutism Fluoxetine 15 NR NR NR NR NR NR NR NR 
1994 Graae et al Anxiety Clonazepam 12 0.0% 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
1994 Kendall et al. Anxiety CBT 47 24.0% 76.0% 24.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
1995 Clarke et al. Depression GCBT 150 7.3% 92.5% 0.0% 0.0% 0.0% 0.0% 0.0% 7.3% 
1996 Kye et al Depression Amitriptyline 31 25.8% 74.2% 16.1% 0.0% 0.0% 0.0% 0.0% 9.7% 
1996 
Treadwell 
and Kendall Anxiety CBT 151 33.5% 66.5% 33.5% 0.0% 0.0% 0.0% 0.0% 0.0% 




NST 107 16.8% 83.2% 0.0% 0.0% 0.0% 0.0% 0.0% 16.8% 
1997 Emslie et al Depression Fluoxetine 96 20.8% 79.2% 0.0% 0.0% 0.0% 0.0% 0.0% 20.8% 
1997 Kendall et al Anxiety CBT 94 14.9% 85.2% 5.6% 2.0% 3.4% 0.0% 0.0% 4.4% 
1997 Sallee et al Depression Clomipramine 16 NR NR NR NR NR NR NR NR 
1997 Weisz et al Depression 
Prim & Sec 
Control 
Enhancement 










Depression Amitriptyline 27 11.1% 88.9% 11.1% 0.0% 0.0% 0.0% 0.0% 0.0% 
1998 Geller et al Bipolar Lithium 25 NR NR NR NR NR NR NR NR 
1998 Geller et al Depression Lithium 30 3.3% 96.7% 0.0% 0.0% 0.0% 0.0% 0.0% 3.3% 
1998 Klein et al Depression Desipramine 45 42.2% 57.8% 8.9% 26.7% 2.2% 0.0% 0.0% 4.4% 
1998 Lamb et al Depression 
School-based 
CBT 41 4.9% 95.1% 0.0% 4.9% 0.0% 0.0% 0.0% 0.0% 
 
 
1998 Last et al 
School 
Refusal CBT 47 10.6% 89.4% 4.3% 6.4% 0.0% 0.0% 0.0% 0.0% 





sessions 96 NR NR NR NR NR NR NR NR 
1999 Mufson et al Depression IPT 48 70.9% 29.2% 0.0% 70.9% 0.0% 0.0% 0.0% 0.0% 
1999 
Silverman et 










support 81 38.3% 61.7% 0.0% 35.8% 0.0% 0.0% 0.0% 2.5% 


















Phobia CBGT 33 NR NR NR NR NR NR NR NR 
2001 Kendall et al Anxiety 
CBT 
(Comorbidity) 165 15.2% 84.8% 15.2% 0.0% 0.0% 0.0% 0.0% 0.0% 
2001 RUPP Group Anxiety Fluvoxamine 128 36.7% 63.3% 7.0% 18.8% 0.0% 0.0% 0.0% 10.9% 
2001 Rynn et al Anxiety Sertraline 22 19.0% 81.0% 0.0% 0.0% 0.0% 0.0% 0.0% 19.0% 
2001 
Thompson et 
al Suicide CARE, CAST 460 51.0% 48.9% 19.0% 10.0% 18.0% 4.0% 0.0% 0.0% 
2002 Clarke et al Depression 
GCBT vs 
usual care 88 9.1% 90.9% 0.0% 0.0% 0.0% 0.0% 0.0% 9.1% 
 
 
2002 DelBello et al Bipolar Quetiapine 30 16.7% 83.3% 0.0% 0.0% 0.0% 0.0% 0.0% 16.7% 
2002 Emslie et al Depression Fluoxetine 219 17.8% 82.2% 6.4% 5.9% 0.5% 0.0% 0.0% 5.0% 
2003 
Birmaher et 
al Anxiety Fluoxetine 74 4.1% 95.9% 0.0% 0.0% 1.4% 0.0% 2.7% 0.0% 
2004 Mufson et al Depression IPT 63 71.4% 28.6% 0.0% 71.4% 0.0% 0.0% 0.0% 0.0% 
2004 TADS Team Depression 
CBT, 
Fluoxetine, 
Both 439 26.2% 73.8% 12.5% 8.9% 0.0% 0.0% 0.0% 4.8% 
2004 Wagner et al Depression Citalopram 174 23.0% 77.0% 0.0% 0.0% 0.0% 0.0% 0.0% 23.0% 
NR = Not reported.                       
 
 
 
